Stocky turns companies like AstraZeneca PLC into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Hold. AZN trades at a reasonable 14.7× forward earnings, supported by a wide moat in oncology and dual-regulatory strength, but the Growth Compounder Score of 58 reflects moderate expansion. The key tension: oncology dominates the portfolio, creating meaningful pipeline replacement risk that limits upside unless near-term launches materially offset this concentration.
How safely AstraZeneca PLC is financed, graded A++ (strongest) to C from the last five years of accounts: debt against earnings, interest cover, cash against debt, how high and steady profit margins are, return on capital, and whether it generated cash every year. Not part of the Stocky score.
Every stock is scored across six dimensions built to answer one question — can this business keep compounding? — without a Bloomberg subscription. Here's the actual snapshot for AstraZeneca PLC:
Quality + moat + leadership + valuation fused into a single 0–100 number. When you see 67/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
We don't claim a backtest. The top-scoring basket is recorded every month and measured against the S&P 500 from that date onward — judged on what it said before the outcome was known. The record is young, and published as it stands.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates AstraZeneca PLC (AZN) at 67/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation into a single number. Hold. AZN trades at a reasonable 14.7× forward earnings, supported by a wide moat in oncology and dual-regulatory strength, but the Growth Compounder Score of 58 reflects moderate expansion. The key tension: oncology dominates the portfolio
AZN's current Stocky Verdict is 67/100, placing it in the "Hold" band. This composite combines a 58/100 Compounder score, 70/100 Leadership, 79/100 Moat rating.
AstraZeneca PLC rates Wide moat (79/100 Moat Score) — based on 10-year return-on-invested-capital, pricing power, switching costs and network effects. Wide moats compound; Limited moats erode.
AstraZeneca PLC scores 70/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
AstraZeneca PLC's Resilience Profile scores 83/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to AstraZeneca PLC.
Sign up free and unlock the full analysis on AZN — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for AZN in the app.
